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Abstract
Introduction: Epigallocatechin-3-gallate (EGCG) is a bioactive polyphenol of green tea and exerts potent anti-
inflammatory effects by inhibiting signaling events and gene expression. Interleukin-1beta (IL-1b) is the principal
cytokine linked to cartilage degradation in osteoarthritis (OA). The objective of this study was to evaluate the
global effect of EGCG on IL-1b-induced expression of proteins associated with OA pathogenesis in human
chondrocytes.
Methods: Primary OA chondrocytes were pretreated with EGCG (10 to 100 uM) and then stimulated with IL-1b
(5 ng/ml) for 24 hours. Culture supernatants were incubated with cytokine antibody arrays and immunoreactive
proteins (80 proteins) were visualized by enhanced chemiluminiscence. Effect of EGCG on IL-1b-induced expression
of 18 selected genes was verified by Real time-PCR and effect on IL-6, IL-8 and tumor necrosis factor-alpha (TNF-a)
production was determined using specific ELISAs. Western immunoblotting was used to analyze the effect of EGCG
on the interleukin-1 receptor-associated kinase 1 (IRAK-1) and TNF receptor-associated factor 6 (TRAF-6) proteins in
IL-1b-stimulated chondrocytes. The role of nuclear factor kappa-B (NF-B) and mitogen activated protein kinases
(MAPKs) in the regulation of selected genes and the mechanism involved in EGCG mediated modulation of these
genes was determined by using specific inhibitors for NF- B (MG132) and MAPKs (p38-MAPK, SB202190; JNK-
MAPK, SP600125, ERK-MAPK, PD98059).
Results: Out of 80 proteins present on the array, constitutive expression of 14% proteins was altered by EGCG
treatment. No significant stimulatory effect was observed on the proteins associated with cartilage anabolic
response. Stimulation with IL-1b enhanced the expression of 29 proteins. Expression of all 29 proteins up-regulated
by IL-1b was found to be suppressed by EGCG. EGCG also inhibited the expression of the signaling intermediate
TRAF-6 at 50 and 100 uM concentrations (P < 0.05). Our results identified several new targets of EGCG, including
epithelial neutrophil activating peptide-78 (ENA-78), granulocyte macrophage colony stimulation factor (GM-CSF),
growth- related oncogene (GRO), GRO-a, IL-6, IL-8, monocyte chemotactic protein-1 (MCP-1), MCP-3, macrophage
inflammatory protein-1beta (MIP-1b), granulocyte chemotactic protein-2 (GCP-2), MIP-3alpha, interferon-gamma-
inducible protein-10 (IP-10), nucleosome assembly protein-2 (NAP-2) and leukemia inhibitory factor (LIF). The
inhibitory effects of EGCG were mainly mediated by inhibiting the activation of NF-B and c-Jun N-terminal Kinase
(JNK)-MAPK in human chondrocytes.
Conclusions: Our results suggest that the potential of EGCG in OA treatment/prevention may be related to its
ability to globally suppress the inflammatory response in human chondrocytes. These results identify additional
new targets of EGCG and advocate that EGCG may be a potent chondroprotective agent in OA.
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Osteoarthritis (OA) is a multifactorial degenerative joint
disease which involves articular cartilage matrix destruc-
tion and for which there is no cure and no useful treat-
ments to block disease progression. The extracellular
matrix of the cartilage is maintained by equilibrium
between anabolic and catabolic activities of the chon-
drocytes - the only cell type present in the cartilage
[1,2]. OA essentially reflects an imbalance between
matrix anabolic and catabolic processes [2,3]. Multiple
pro-inflammatory cytokines such as IL-1b,T N F - a,I L - 6
and chemokines (IL-8 and others) are produced by acti-
vated chondrocytes in OA [3-6]. IL-8 is a chemoattrac-
tant factor involved in synovial inflammation in the
joint [4] and IL-6 reportedly plays a contributory role to
the OA pathogenesis by increasing the number of
inflammatory cells in synovial tissue, stimulating prolif-
eration of chondrocytes, and inducing amplification of
IL-1 effects [6]. IL-1b is an inflammatory cytokine and
its inhibition has been shown to ameliorate osteoarthri-
tis-like pathology in animal models [7,8]. Further, the
role of IL-1b in OA pathogenesis was also been substan-
tiated by studies in IL-1 deficient mice [7,8]. Thus, IL-1b
can shift the balance between the biosynthesis and the
degradation of extracellular matrix components (via pro-
duction of matrix metalloproteinases (MMPs), and dis-
integrin and metalloproteinase with thrombospondin
motifs [ADAMTSs], in the cartilage and transform
chondrocytes to display the catabolic phenotype seen in
OA [3]. Such an imbalance between the anabolism and
catabolism of the extracellular matrix is thought to lead
to the disruption of cartilage homeostasis and favors
degradation, culminating in the loss of joint function
[1,9]. The beneficial effects ascribed to drinking green
tea (Camellia sinensis) are believed to rely on the phar-
macological actions of catechins. Green tea is a rich
source of catechins and EGCG constitutes up to 63% of
total catechins [10]. EGCG has been shown to be 25 to
100 times more potent than vitamins C and E in anti-
oxidant activity [11]. Earlier studies have demonstrated
the potential chondroprotective effects of EGCG in vitro
[12-14]. In addition, we have also reported the preven-
tion of inflammatory arthritis by a polyphenol rich
extract of green tea in a mouse model of RA [15].
EGCG has been shown to inhibit metalloproteinases
[16], nitric oxide [14], cyclooxygenase-2 (COX-2) and
production of prostaglandin E2 [14], activation of
nuclear factor-kappaB (NF-B) [12], mitogen activated
protein kinases (MAPKs) [13] and activator protein-1
(AP-1) [13] in IL-1b stimulated human OA chondro-
cytes. In the present study, we used antibody based
arrays to analyze the global effect of EGCG on IL-1b-
induced expression of growth factors, angiogenic factors,
cytokines and chemokines in human OA chondrocytes
and validated the effect on gene expression of selected
proteins by real-time PCR. Our data suggest that EGCG
exerts a wide ranging effect on the expression of pro-
teins associated with OA pathogenesis and correlated
with the inhibition of NF-B and MAPKs in human OA
chondrocytes. Our results also identify several new tar-
gets of EGCG and its unique mechanism of action on
these pro-inflammatory genes and suggest the use of
EGCG may be of value in the prevention/treatment of
inflammation associated with OA.
Materials and methods
Cartilage sample and culture of chondrocytes
This protocol to use discarded and de-identified human
cartilage was reviewed by the Institutional Review Board
(IRB) of the MetroHealth Medical Center, which classi-
fied it as exempt from review and that informed consent
was not required (IRB09-01330). Human chondrocytes
were prepared by enzymatic digestion of cartilage
obtained from 15 OA patients (mean age, 60.6 ± 4.7
years) undergoing knee arthroplasty at the MetroHealth
Medical Center, Cleveland, OH. OA was diagnosed
according to the American College of Rheumatology cri-
teria [17,18]. Specimens that included the full thickness
cartilage and subchondral bone were washed with sterile
PBS and the macroscopic cartilage degeneration was
determined by staining with India ink [19]. Portions of
the cartilage with smooth articular surface were used to
prepare chondrocytes by the enzymatic digestion with
pronase for two hours followed by collagenase digestion
overnight as previously described [12,20]. Primary OA
chondrocytes at 80% confluence were used for all the
studies described here. Primary OA chondrocytes from
different patients were studied for COL2A1, ACAN and
COL10A1 expression by qRT-PCR. They showed the
chondrogenic phenotype by expressing COL2A1 and
ACAN without expression of COL10A1 (data not
shown).
Treatment of chondrocytes with IL-1b and EGCG
OA chondrocytes (1 × 10
6/ml) were serum starved in
Ham’s F-12 starving medium for 12 h and were treated
with EGCG (100 μM) for 2 h prior to stimulation with
IL-1b (5 ng/ml) for different periods of time. OA chon-
drocytes cultured without IL-1b or EGCG served as
controls. Concentration of EGCG was selected on the
basis of our previous studies where EGCG (100 μM)
showed effective anti-inflammatory effects without
affecting cell viability [12-14]. Culture supernatants were
used for the antibody array analysis.
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NO production was estimated spectrophotometrically by
measuring the accumulation of nitrites in the culture
supernatants by Griess reaction [21]. Briefly, 100 μlo f
culture supernatant were mixed with 100 μlo fG r i e s s
reagent (1% of sulfanilamide in 2.5% H3PO4 and 0.1% of
N-Naphthylethylenediamine dihydrochloride in H2O, v/
v) for five minutes at room temperature in micro titer
plates. The absorbance was measured at 550 nm with
microplate reader (Synergy HT, BioTek Instruments
Inc., Winooski, VT, USA), and nitrite concentration was
calculated using a standard curve prepared with sodium
nitrite.
Protein antibody array
We used a commercial antibody-based array designed to
detect 80 different proteins including growth factors,
cytokines and chemokines (RayBio Human Cytokine
Array V, RayBiotech, Norcross, GA, USA). Experiments
were performed essentially as recommended by the
manufacturer. Briefly, array membranes were incubated
for 30 minutes in 2 ml blocking buffer, then incubated
overnight with 1 ml of the culture supernatant and
washed. Then, a cocktail of 80 biotinylated antibodies
diluted 1:250 was added at 1 ml per array membrane
and membranes were kept at 4°C overnight. Membranes
were washed and sandwiched antigens were detected by
enhanced chemiluminescence by incubating the mem-
branes for two hours with 2 ml of a peroxidase-labeled
streptavidin solution (diluted 1:1000) and signals were
captured on X-ray films. Arrays that received samples
stimulated with either IL-1b or EGCG alone or in com-
bination were processed simultaneously for image
acquisition.
Validation of results
Each spot of the array membrane was quantified by the
image analysis software UN-Scan-It (Silk Scientific,
Orem, UT, USA) in triplicate with background correc-
tion and the mean value was used. The detection of pro-
tein spots on microarrays is a semi-quantitative method.
Thus normalization can be used to compare the data
between arrays (representing different samples) by
accounting for the difference in signal intensities on the
two arrays as measured by the signals from the positive
controls on those arrays. It is important to note that
this assay does not measure the absolute concentration
of proteins but the normalized signal intensities can be
compared to provide measurement of relative concen-
tration in each sample. Positive control has a controlled
amount of biotinylated antibody that is attached to the
membrane itself and the signal intensity of those spots
are dependent on the amount of streptavidin-HRP
bound to the antibody and length of exposure time for
the detection. Since these factors proportionately affect
the absolute signal density of every spot on the array,
t h er e l a t i v ed i f f e r e n c ei nt h ep o s i t i v ec o n t r o ls i g n a l s
between arrays will be proportional to the difference in
signal between other pairs of corresponding spots on
the two arrays. Normalized values were calculated by
the formula: X (Ny) = X(y) * P1/P(y). P1 = average sig-
nal density of the positive control spot on the reference
array. P(y) = average signal density of the positive con-
trol spot on array “y”. X(y) = signal density for a parti-
cular spot on array for sample “y”. X (Ny) = normalized
value of the particular spot “X” on array for sample “y”.
Enzyme linked immune-sorbant assays (ELISA)
The effect of IL-1b and/or EGCG (100 μM) on the level
of IL-6, IL-8 and TNF-a secreted by chondrocytes in
the culture medium was further confirmed by ELISAs
(R&D Systems, Minneapolis, MN, USA) and all the
assays were performed according to the manufacturer’s
instructions. Limit of detection for IL-6, IL-8 and
TNF-a, was > 0.7 pg/ml, 3.5 pg/ml and 1.6 pg/ml
respectively.
NF-B DNA binding activity assay
Activation of NF-B p65 in OA chondrocytes was deter-
mined using a highly sensitive transcription factor
ELISA kit according to the instructions of the manufac-
t u r e r( A s s a yD e s i g n s ,A n nA r b o r ,M I ,U S A ) .T h i sa s s a y
uses streptavidin-coated plates with bound NF-B-bioti-
nylated consensus sequence to capture the active form
of NF-B. The captured active NF-B is incubated with
a specific antibody. The assay was developed with a che-
miluminescent substrate and the signal was detected
using a luminometer (Lumat LB 9507; Berthold Tech-
nologies, Bad Wildbad, Germany), and the values are
expressed as relative light units (RLU).
Quantitative real-time-PCR (RT-PCR)
Real time quantitative-PCR was used to quantify the
gene expression of mRNAs for IL-6, IL-8 and TNF-a
and other genes with expression of GAPDH used as
endogenous control. Total RNA was isolated from OA
chondrocytes by TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’si n s t r u c t i o n .
First-strand cDNA was synthesized using 1 μgo ft o t a l
RNA and the SuperScript First-Strand cDNA synthesis
kit (Invitrogen). PCR amplification was carried out using
specific primers (Additional file Table 2), the core kit
for SYBR Green (Quanta Biosciences, Gaithersburg,
MD, USA) and the Step One Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Typical
profile times used were initial step, 95°C for 10 minutes
followed by a second step at 95°C for 15 s and 60°C for
30 s for 40 cycles with melting curve analysis. The level
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and compared with control. Data were analyzed using
ΔΔCT method [22].
Western blotting and densitometric analysis
IL-1b-stimulated and control OA chondrocytes were
washed with cold PBS and lysed using the cell lysis buf-
fer (50 mM Tris:HCl, pH 7.4; 150 mM NaCl; 1% Triton
X-100;0.1% SDS; 0.5% sodium deoxycholate; 1 mM
EDTA; 1 mM EGTA; Complete
® protease and phospha-
tase inhibitors) as previously described [23,24]. Total
lysate protein (40 μg/lane) was resolved by SDS-PAGE
(10% resolving gel with 4% stacking) and transferred to
nitrocellulose membranes (BioRad, Hercules, CA, USA).
Membranes were blocked with blocking buffer contain-
ing non-fat dry milk powder in Tris buffered saline with
0.1% Tween-20 (TBS-T), and probed with 1:500 and
1:1,000 diluted primary antibodies (1:500 to 1:1,000)
specific for the target proteins. Immunoreactive proteins
were visualized by using 1:5,000 diluted HRP-linked sec-
ondary antibodies and enhanced chemiluminescence
(GE Health Care, Milwaukee, WI, USA). Bands were
scanned and the analysis was performed using Un-Scan-
It software. Each band was scanned three times and
data were normalized to loading control and expressed
as mean ± SD followed by appropriate statistical
analysis.
Statistical analysis
All experiments were performed in duplicate and
repeated three times using independent samples. Values
shown are mean ± SE unless stated otherwise. Compari-
sons were performed using Origin 8.1 software package
(OriginLab Corporation, Northampton, MA, USA) (one-
paired two-tailed t-test with one way ANOVA and
Tukey’s post-hoc analysis) and P < 0.05 was considered
significant.
Results
Nitrite level in IL-1b stimulated OA chondrocytes and
effects of EGCG
Previously, we have shown that EGCG is an effective
inhibitor of IL-1b induced nitric oxide (NO) production
in chondrocytes [12] and the concentration of EGCG
used (100 μM) was not cytotoxic in 24-hour cultures
[13]. To ensure that subsequent protein microarray data
provided an accurate representation of the effect of
EGCG and IL-1b on chondrocytes, nitrite levels were
used as surrogate for NO expression induced by IL-1b
and the effect of EGCG on NO expression to verify that
the chondrocytes responded reproducibly to both the
molecules. As shown in Additional file 1a, nitrite levels
significantly increased (P < 0.05) upon IL-1b (5 ng/ml)
stimulation of OA chondrocytes for 24 hours.
Pretreatment of OA chondrocytes with EGCG signifi-
cantly inhibited (P < 0.05) the IL-1b-induced production
of NO in human OA chondrocytes confirming the pre-
viously reported results.
Effect of EGCG alone on OA chondrocytes
Of the 80 proteins present on the antibody array, treat-
ment with EGCG alone showed no significant change (P
< 0.05) in the expression of 69 proteins (approximately
86%) relative to control chondrocytes. However, expres-
sion of 11 proteins (approximately 14%; P < 0.05) was
found to be altered upon EGCG treatment. Representa-
tive antibody array data, showing effects of EGCG alone
on the expression of different proteins in OA chondro-
cytes are shown in Additional file 1b, e). For the array
layout and identification of cytokines please see Addi-
tional file 2. The constitutive expression of IL-6 in OA
chondrocytes was significantly down regulated (Figure 1;
P < 0.05) by EGCG treatment, which also significantly
reduced (P < 0.05) the basal level of some chemokines
(Figure 2) such as growth related oncogene (GRO),
GRO-a, monocyte chemoattractant protein-1 (MCP-1/
CCL2), interleukin-8 (IL-8/CXCL-8), and macrophage
inflammatory protein-1b (MIP-1b/CCL4). EGCG also
significantly reduced the constitutive production of
angiogenin, osteoprotegrin and osteopontin compared to
control chondrocytes (Figure 3; P < 0.05). OA chondro-
cytes also constitutively expressed the TIMP-1 and
TIMP-2 proteins but their expression was significantly
inhibited by EGCG (Figure 3; P < 0.05).
Effect of IL-1b on the expression of inflammatory and
catabolic proteins in OA chondrocytes
Treatment of OA chondrocytes with IL-1b resulted in
the altered expression of 29 proteins (approximately
36%; Additional file 1b, c, P < 0.05). Several specific
observations should be mentioned here: (i) chondro-
cytes stimulated with IL-1b (5 ng/ml) showed a several
fold increase in the expression of granulocyte-macro-
phages colony stimulating factor (GM-CSF), G-CSF,
macrophages colony stimulating factor (M-CSF), inter-
leukin-6 (IL-6), IL-7, oncostatin M and leukemia inhi-
bitory factor (LIF) (Figure 1; P <0 . 0 5 ) .As l i g h t
increase was also observed in the expression of tumor
necrosis factor-a (TNF-a)c o m p a r e dt ou n - s t i m u l a t e d
chondrocytes (Figure 1; P < 0.05). (ii) High level
expression of some chemokines was also actively
induced (Figure 2; P <0 . 0 5 )b yI L - 1 b including epithe-
lial neutrophil activating peptide-78 (ENA-78/CXCL5),
GRO, GRO-a,M C P - 1 ,I L - 8 ,M I P - 1 b,M I P - 3 a,n u c l e o -
some assembly protein-2 (NAP-2/CXCL7) and granu-
locyte chemotactic protein-2 (GCP-2/CXCL6) in OA
chondrocytes. IL-1b-stimulation of OA chondrocytes
also showed significant up-regulation of MCP-2
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3, while the expression of I-309, RANTES and MCP-4
was not significantly induced by IL-1b-stimulation of
OA chondrocytes (Figure 2; P < 0.05). (iii) Some pro-
teins known to be involved in extracellular matrix
remodeling including tissue inhibitors of MMPs
(TIMPs), growth and angiogenic factors were also sig-
nificantly up-regulated by IL-1b a n dt h i si n c l u d e sv a s -
cular endothelial growth factor (VEGF), IGFBP-1,
thrombopoietin, angiogenin, and TIMP-2 (Figure 3; P
< 0.05). In contrast, a decrease or no effect on the
expression of proteins associated with matrix remodel-
ling including osteoprotegrin and TIMP-1 was
observed upon IL-1b-stimulation of OA chondrocytes
(Figure 3; P < 0.05).
Effect of EGCG on IL-1b-induced protein expression in OA
chondrocytes
Additional file 1c, d showed the comparative expres-
sion pattern of proteins between IL-1b stimulated
chondrocytes in the presence and absence of EGCG.
Treatment of OA chondrocytes with EGCG prior to
stimulation with IL-1b proved to be surprisingly potent
and a broad spectrum inhibitor of IL-1b-induced
expression of different cytokines and other proteins in
human OA chondrocytes. Overall, relative to IL-1b-sti-
mulated chondrocytes where 28 proteins were signifi-
cantly up-regulated, treatment with EGCG down
regulated the expression of all the up-regulated pro-
teins (Figures 1, 2 and 3). Pretreatment of OA chon-
drocytes with EGCG, markedly reduced the IL-1b-
induced production of GM-CSF, MC-SF, LIF, IL-6, IL-
7a n do n c o s t a t i nM( F i g u r e1 ;P < 0.05). Pretreatment
with EGCG also significantly reduced the expression of
TNF-a, and G-CSF in OA chondrocytes stimulated
with IL-1b (Figure 1; P < 0.05). Results of antibody
array showed increased IL-1b in IL-1 stimulated chon-
drocytes, but EGCG pretreatment significantly inhib-
ited (P <0 . 0 5 )t h eI L - 1 b levels in culture supernatants
(Additional file 1e). EGCG pretreatment of OA
Figure 1 Inhibition of IL-1b induced cytokine expression in human OA chondrocytes by EGCG (a, b). Chondrocytes were pretreated for 2
h with EGCG (100 μM) and then stimulated or not stimulated with IL-1b (5 ng/ml) for 24 h. Values represent Mean ± SE of three different
patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. EGCG, epigallocatechin-3-gallate; GCSF, granulocyte
colony stimulating factor; GM-CSF, granulocyte-macrophages colony stimulating factor; IFN-g, interferon-g; IL, interleukin; LIF, leukemia inhibitory
factor; MCSF, macrophages colony stimulating factor; MIF, macrophage migratory inhibitory factor; TNF, tumor necrosis factor.
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on the production of ENA-78, GRO, GRO-a,I L - 8 ,
MIP-1b,M I P - 3 a, MCP-1, GCP-2, NAP-2 and moder-
ate inhibitory effect on MCP-2 and 3, eotaxin 3 and
IP-10 production (Figure 2; P < 0.05). Interestingly,
EGCG also significantly inhibited the level of angio-
genin, thrombopoeitin, VEGF, TIMP-1 and 2, IGFBP-1
in IL-1-stimulated OA chondrocytes (Figure 3; P <
0.05). Although, IL-1b significantly down-regulated the
expression of osteoprotegrin, EGCG alone also seems
to reduce its constitutive production in OA chondro-
cytes (Figure 3; P < 0.05).
Effect of EGCG on the expression and production of IL-6,
IL-8 and TNF-a in chondrocytes
Based on the data obtained by antibody arrays, we
selected IL-6, IL-8 and TNF-a expression for further
confirmation as these proteins have pathophysiological
relevance to OA severity and progression. Chondrocytes
were pretreated with EGCG (10 to 100 μM) for 2 h and
then stimulated with IL-1b for 8 h for mRNA expres-
sion (except for TNF-a mRNA which was done at 24 h)
and 24 h for protein production. As shown in Figure-4a,
pretreatment with EGCG (10 to 100 μM) dose depen-
dently inhibited the IL-1b-induced mRNA expression of
IL-6 (P < 0.05). To determine whether this inhibition of
gene expression also influenced the production of IL-6
protein culture supernatants were assayed using IL-6-
specific ELISA. Pretreatment with EGCG (10 to 100
μM) also significantly inhibited the IL-6 production in
culture supernatants of stimulated chondrocytes (Figure
4d; P < 0.05). Additionally, EGCG pretreatment signifi-
cantly reduced the basal level of IL-6 production by OA
chondrocytes (Figure 4d; P < 0.05).
Our results showed that chondrocytes treated with IL-
1b had significantly higher expression of IL-8 mRNA
similar to protein microarray results, in comparison to
un-stimulated chondrocytes (Figure 4b; P <0 . 0 5 ) .
Figure 2 Effect of EGCG on IL-1b stimulated secretion of chemokines in human OA chondrocytes (a-b). Chondrocytes were pretreated for
2 h with EGCG (100 μM) and then stimulated or not stimulated with IL-1b (5 ng/ml) for 24 h. Values represent Mean ± SE of three different
patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. BLC, B-lymphocyte chemoattractant; EGCG,
epigallocatechin-3-gallate; ENA-78, epithelial neutrophil activating peptide-78; GCP-2, granulocyte chemotactic protein-2; GRO, growth-related
oncogene; IL- interleukin; MCP, monocyte chemotactic protein; MDC, macrophage-derived chemokine; MIG, monokine induced by interferon-
gamma; MIP, macrophage inflammatory protein; NAP-2, nucleosome assembly protein-2; RANTES, regulated upon activation normal T-cell
expressed and secreted;IP-10,10 kDa interferon gamma-induced protein.
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decline in chondrocytes pretreated with different con-
centration of EGCG (Figure 4b; P < 0.05). When culture
supernatants were analyzed for IL-8 protein levels
results were similar to those obtained with IL-8 mRNA
expression. (Figure 4e; P < 0.05). In agreement with the
protein array results EGCG also significantly reduced
the basal level of IL-8 (Figure 4e; P < 0.05). Pretreat-
ment of chondrocytes with EGCG (50 and 100 μM) also
significantly inhibited the IL-1b induced mRNA expres-
sion of TNF-a compared to IL-1b-stimulated OA chon-
drocytes (Figure 4c; P < 0.05). Pretreatment with EGCG
showed a dose dependent decrease in the level of TNF-
a protein production in IL-1b-stimulated OA chondro-
cytes (Figure 4f; P < 0.05).
Role of nuclear factor-kappaB (NF-B) and mitogen
activated protein kinase (MAPKs) pathways in EGCG
mediated inhibition of IL-6, IL-8 and TNF-a in IL-1b-
stimulated OA chondrocytes
NF-B is an important transcriptional regulator of
inflammatory gene expression and plays a crucial role in
immune and inflammatory response. However, activa-
tion of MAPKs is also intimately associated with the
expression of pro-inflammatory genes. As shown in Fig-
ure 5a, EGCG significantly (P < 0.05) inhibited the IL-
1b-induced activation of NF-B in OA chondrocytes as
previously reported [12,25]. As IL-6, IL-8 and TNF-a
genes are NF-B dependent; its inhibition by EGCG
provides an explanation for the inhibition of IL-6, IL-8
and TNF-a expression in OA chondrocytes. EGCG also
Figure 3 Effect of EGCG on secretion of growth and angiogenic factors in human OA chondrocytes stimulated with IL-1b (a, b).
Chondrocytes were pretreated for 2 h with EGCG (100 μM) and then stimulated or not stimulated with IL-1b (5 ng/ml) for 24 h. Values
represent Mean ± SE of three different patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. BDNF, brain-
derived neurotrophic factor; EGCG, epigallocatechin-3-gallate; EGF, endothelial growth factor; FGF, fibroblast growth factor; GDNF, glial cell
derived neurotrophic factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; NT,
neurotrophin; PDGF-BB, platelet-derived growth factor receptor, beta polypeptide subunit B; PIGF, phosphatidylinositol glycan anchor
biosynthesis; TGF, transforming growth factor; TIMP, tissue inhibitor of MMPs; VEGF, vascular endothelial growth factor.
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( F i g u r e5 b )[ 1 3 ] ;w ea l s os t u d i e dt h er o l eo fM A P K si n
IL-1b-induced expression of IL-6, IL-8 and TNF-a in
OA chondrocytes. We used the pharmacological agents,
MG132 (NF-B inhibitor), SB202190 (p38-MAPK inhi-
bitor), SP600125 (JNK-MAPK inhibitor) and PD98059
(ERK inhibitor) to dissect the role of individual MAPKs
in the expression of IL-6, IL-8 and TNF-a in OA chon-
drocytes. Treatment of OA chondrocytes with the pro-
teasome inhibitor MG132, blocked the IL-1b-induced
IL-6, IL-8 and TNF-a expression as determined by
quantitative real-time PCR (Figures 5c, d and 5e; P <
0.05). When the role of individual MAPKs inhibition
and expression of IL-6, IL-8 and TNF-a in OA chon-
drocytes was studied, we found that the activation of
p38-MAPK was essential for the optimal expression of
IL-6, IL-8 and TNF-a as inhibition of p38-MAPK
nearly obliterated their expression in IL-1b-treated OA
chondrocytes (Figures 5 c, d and 5e). Inhibition of JNK
activation in OA chondrocytes also down-regulated the
IL-1b-induced expression of IL-6 but the effect was
not as dramatic as was obtained with p38 MAPK inhi-
bition (Figure 5c; P < 0.05). Inhibition of ERK
activation showed virtually no inhibition of IL-6, IL-8
and TNF-a gene expression in IL-1b-treated OA chon-
drocytes indicating that ERK activation is not essential
for their expression. Thus, inhibitory effects of EGCG
on IL-6, IL-8 and TNF-a expression may be related to
the inhibition of NF-B and JNK activation in IL-1b-
stimulated OA chondrocytes. These results also
demonstrate that inhibition of IL-6, IL-8 and TNF-a
can also be targeted via inhibition of p38-MAPK with-
out inhibiting NF-B.
Effect of EGCG on the expression of TRAF-6 and IRAK-1 in
IL-1b-stimulated OA chondrocytes
TRAF-6 and IRAK-1 are important signaling intermedi-
ates in transducing signals to the cell after the binding IL-
1 to IL-1R on the cell surface. OA chondrocytes were pre-
treated with EGCG (10 to 100 μM) for one hour and then
stimulated with IL-1b for one half-hour for both mRNA
expression and protein production. Treatment with IL-1b
caused significant increase in TRAF-6 protein expression,
whereas pre-incubation with 50 and 100 μMc o n c e n t r a -
tion of EGCG appeared to inhibit TRAF-6 protein expres-
sion significantly, which is consistent with the significant
Figure 4 Effect of EGCG IL-6, IL-8 and TNF-a gene expression and production in IL-1b-stimulated human OA chondrocytes.
Chondrocytes were pretreated with EGCG (10 to 100 μM) for 2 h and stimulated with IL-1b for (a, b) 8ho r(c, d, e, and f) 24 h. Gene
expression for IL-6, IL-8 and TNF-a was determined by quantitative RT-PCR normalized to GAPDH and then compared with the levels present in
un-stimulated chondrocytes. Levels of IL-6, IL-8 and TNF-a in the culture supernatants were quantified by sandwich ELISA. Value represents Mean
± SE of three different patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. EGCG, epigallocatechin-3-gallate;
IL-interleukin; TNF, tumor necrosis factor.
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chondrocytes pre-treated with EGCG (Figure 6a, b; P <
0.05). EGCG pretreatment did not show any significant
change on IRAK-1 mRNA expression in OA chondrocytes
stimulated with IL-1b (Figure 6c). Treatment with IL-1b
in OA chondrocytes completely degraded the IRAK-1 pro-
tein compared to un-stimulated OA chondrocytes (Figure
6d; P < 0.05), whereas pre-incubation with 50 and 100 μM
concentrations of EGCG inhibited the IL-1b-induced
degradation of IRAK-1 (Figure 6d).
Real-time PCR verification
In order to confirm the effects of EGCG obtained by
protein array analysis, the expression of 15 additional
genes was also analyzed by real-time PCR (Figure 7a-o).
The primer sequences for the genes verified by RT-PCR
are given in Additional file 3. This analysis demon-
strated a significant inhibitory effect of EGCG on the
expression pattern of all the genes analyzed (Figure 7; P
< 0.05) except MCP-2 (Figure 7j), which in contrast
with the array results was not found to be down regu-
lated by EGCG in IL-1b-stimulated OA chondrocytes
(Figure 2; P < 0.05). Among the genes whose expression
was verified by real-time PCR analysis, EGCG appeared
to inhibit the expression of GM-CSF, GRO, GRO-a and
IP-10 maximally in IL-1b-stimulated OA chondrocytes
in agreement with the results shown above.
Role of NF-B pathways in EGCG mediated inhibition of
verified genes in IL-1b-stimulated OA chondrocytes
A large body of direct and indirect evidence links the
NF-B pathway to the inflammation and cartilage
degeneration in OA. Thus, inhibition of NF-Bh o l d s
promise in regulating IL-1b-induced inflammatory
response in human OA chondrocytes [3,26]. We also
studied the effect of NF-B inhibitor (MG132) on the
expression of LIF, IL-7, GM-CSF, ENA-78, GRO, GRO-
a,M C P - 1 ,M C P - 2 ,M C P - 3 ,M I P - 1 b, IP-10, GCP-2, and
NAP-2. As shown in Figures 8, 9 and 10, stimulation
with IL-1b significantly increased the mRNA expression
levels of all of these genes (P < 0.05). Interestingly,
blockage of NF-B activation in IL-1b-stimulated OA
chondrocytes caused a significant decrease in the
expression of all of them (P < 0.05). Further, inhibition
of NF-B activation in OA chondrocytes treated with
MG132, but not stimulated with IL-1b,a l s oc a u s e da
significant decrease in the constitutive expression of IL-
7, GM-CSF, ENA-78, GRO-a,M C P - 1 ,M C P - 2 ,I P - 1 0
and GCP-2 (P < 0.05). As EGCG is an effective inhibitor
of NF-B( F i g u r e5 a ;P < 0.05) [12], the inhibitory
effects of EGCG on the expression of these genes in IL-
1b-stimulated OA chondrocytes could be due to the
inhibition of NF-B activation.
Role of MAPKs in regulation of gene expression and their
modulation by EGCG in IL-1b-stimulated OA chondrocytes
We have previously shown that EGCG inhibits JNK
phosphorylation (Figure 5b) in IL-1b-stimulated OA
chondrocytes but has no effect on p38- or ERK-MAPKs
Figure 5 EGCG mediated inhibition of NF-Ba n dM A P K si nI L -
1b stimulated human OA chondrocytes and regulation of IL-6,
IL-8 and TNF-a. (a) Human OA chondrocytes were pretreated with
EGCG (10 to 100 μM) for 2 h and stimulated with IL-1b for 24 h. NF-
Bp65 was determined in cell lysate by highly sensitive and specific
ELISA (Assay design). TNF-a-treated extract of HeLa cells (supplied
with the kit) was used as a positive control. The assay is developed
with a chemiluminescent substrate and the signal is detected using
luminometer (Lumat LB 9507; Berthold Technologies). NF-B p65
activity was expressed as relative light unit (RLU). (b) After
pretreatment with EGCG (10 to 100 μM) for one hour, chondrocytes
were stimulated with IL-1b for one half-hour, and then
phosphorylation of JNK, ERK and p38-MAPK was determined by
Western immunobloting. (c, d, and e) Effect of specific inhibitors for
mitogen activated protein kinases and NF-B on the gene
expression of IL-6, IL-8 and TNF-a in IL-1b stimulated human OA
chondrocytes. Primary chondrocytes were pretreated with specific
inhibitors for 2 h and were stimulated with IL-1b for 6 h. Relative
gene expression of IL-6, IL-8 and TNF-a normalized to GAPDH and
compared with un-stimulated control, were determined by
quantitative RT-PCR. Concentrations of specific inhibitors of p38
(SB202190), JNK (SP600125), ERK (PD98059) and NF-B (MG132) used
in these studies were 100 μM, 10 μM, 50 μM and 100 μM,
respectively. Value represents Mean ± SE of three different patients.
# represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated
chondrocytes. EGCG, epigallocatechin-3-gallate;IL-interleukin; ERK,
extracellular signal-regulated kinases; JNK, cJun-N-termial Kinases;
MAPKs, mitogen activated protein kinases; NF-B, nuclear factor
kappa-B; TNF, tumor necrosis factor.
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the regulation of the newly identified genes induced by
IL-1b in OA chondrocytes and the possible role of
EGCG in their modulation via MAPKs. As shown in
Figures 8, 9 and 10, IL-1b significantly increased the
constitutive expression levels of all of these genes in OA
chondrocytes (P < 0.05) in agreement with the array
results. When the effect of MAPKs inhibition on the
regulation of LIF and MCP-3 was studied in IL-1b-trea-
ted OA chondrocytes, inhibition of JNK-and ERK-
MAPK (SP600125 and PD98059, respectively) was found
to be necessary for a significant down-regulation of IL-
1b-induced LIF and MCP-3 expression (P <0 . 0 5 ) .
While inhibition of JNK alone resulted in significant
down-regulation of IL-1b-induced IL-7, MIP-1b, MCP-2
and NAP-2 mRNA expression in OA chondrocytes (P <
0.05), inhibtion of p38-MAPK alone (SB202190) was
sufficient to inhibit IL-1b-induced expression of GRO-a,
I P - 1 0a n dG C P - 2m R N As i g n i f i c a n t l y( P <0 . 0 5 )i n
OA chondrocytes. Treatment of OA chondrocytes with
IL-1b and p38- and JNK-MAPK inhibitors significantly
inhibited the mRNA expression of MCP-1 (P < 0.05). The
expression of ENA-78, GM-CSF and GRO was found to
be regulated by p38, JNK and ERK-MAPKs (P <0 . 0 5 )i n
IL-1b-stimulated OA chondrocytes.
Discussion
EGCG, a bioactive component of green tea has been
shown to possess anti-cancer and anti-inflammatory
activity with a potential for anti-arthritic effects and is
Figure 6 Gene expression and production of TRAF-6 and IRAK-1 in IL-1b-stimulated human OA chondrocytes. (a) and (c) Effect of EGCG
pretreatment on the gene expression of TRAF-6 and IRAK-1 in IL-1b-stimulated OA chondrocytes, respectively. (b) and (d) Effect of EGCG on the
production of TRAF-6 and IRAK-1 in IL-1b-stimulated OA chondrocytes, respectively. Value represents Mean ± SD of three different patients. #
represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. EGCG, epigallocatechin-3-gallate; IL, interleukin; IRAK-1, interleukin-1
receptor-associated kinase 1; TRAF-6, TNF receptor-associated factor 6.
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kines have been implicated in causing synovial tissue
activation and damage to cartilage and subchondral
bone in OA [28]. The most widely investigated cytokine
in OA is IL-1b, because it strongly induces cartilage
catabolic agents [3,6], and inhibits proteoglycan and col-
lagen synthesis [29]. In this study, a spectrum of biologi-
cal effects of EGCG are described for the first time that
provide evidence of modulation of cartilage protective
and inflammation suppressing events by EGCG in IL-
1b-stimulated OA chondrocytes. In addition, several
new genes were found to be induced by IL-1b in OA
chondrocytes and their modulation by EGCG was
studied.
We used the larger screening capacity of the array
technology to analyze for changes in cytokines levels
induced by IL-1b in OA chondrocytes, and to search for
their possible modulation by EGCG. Our test system
had limitations in that the screening was only limited to
80 cytokines (broadly defined) and some mediators with
pathophysiological relevance to OA may have been
neglected. However, the protein array technology is easy
to use and supported by the specificity of protein
recognition by antibodies. Moreover, we used nitrite
production as an indicator of chondrocytes activation by
IL-1b and its suppression by EGCG [12], to demonstrate
that the concentrations of IL-1b a n dE G C Gu s e dw e r e
sufficient to induce and detect the change in cellular
response. Unlike the dramatic response of IL-1b alone,
pre-incubation of chondrocytes with EGCG rendered
the chondrocytes essentially unresponsive to subsequent
IL-1b stimulation, and thereby EGCG appeared to be
highly chondroprotective.
Our results showed the increased IL-1b levels in IL-1b
stimulated OA chondrocytes, but EGCG pretreatment
inhibited the IL-1b mRNA and protein levels in OA
chondrocytes. These results suggest that there may be a
direct inhibitory effect of EGCG on IL-1b expression.
Figure 7 Real-time PCR verification of the expression of IL-1b.
(a), LIF (b), IL-7 (c), GM-CSF (d), RANTES (e), ENA-78 (f), GRO (g),
GRO-a (h), MCP-1 (i), MCP-2 (j), MCP-3 (k), MIP-1b (l), IP-10 (m),
GCP-2 (n), NAP-2 (o). Value represents Mean ± SD of three different
patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b
stimulated chondrocytes. ENA-78, epithelial neutrophil activating
peptide-78; GCP-2, granulocyte chemotactic protein-2; GM-CSF,
granulocyte-macrophages colony stimulating factor; GRO, growth-
related oncogene; IL-interleukin; IP-10,10 kDa interferon gamma-
induced protein; LIF, leukemia inhibitory factor; MCP, monocyte
chemotactic protein; MIP, macrophage inflammatory protein; NAP-2,
nucleosome assembly protein-2; RANTES, regulated upon activation
normal T-cell expressed and secreted.
Figure 8 Effect of specific inhibitors of MAPKs and NF-B
pathways on the gene expression of pro-inflammatory
cytokines and chemokines in IL-1b-stimulated human OA
chondrocytes. Primary chondrocytes were pretreated with specific
inhibitors for 2 h and were stimulated with IL-1b for 6 h. Relative
gene expression of LIF (a), IL-7 (b), GM-CSF (c), ENA-78 (d) and GRO
(e) was normalized to GAPDH and compared with un-stimulated
control, were determined by quantitative RT-PCR. Concentrations of
specific inhibitors of p38 (SB202190), JNK (SP600125), ERK (PD98059)
and NF-B (MG132) used in these studies were 100 μM, 10 μM, 50
μM and 100 μM, respectively. Value represents Mean ± SD of three
different patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-
1b stimulated chondrocytes. ENA-78, epithelial neutrophil activating
peptide-78; GM-CSF, granulocyte-macrophages colony stimulating
factor; GRO, growth-related oncogene; IL-interleukin; LIF, leukemia
inhibitory factor; MAPKs, mitogen activated protein kinases; NF-B,
nuclear factor kappa-B.
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(50 mg/L) inhibited the expression of IL-1b mRNA and
reduced the IL-1b level at cutaneous wound sites in a
mouse model [30]. Adaptor proteins involved in IL-1
signaling such as IRAK and TRAF-6, may also constitute
important therapeutic targets for OA. Phophorylated
IRAK becomes associated with TRAF6, which is a
downstream transducer required for NF-B activation
[31]. Our results showed that treatment with IL-1b
caused a significant increase in TRAF-6 protein, whereas
pre-incubation with EGCG inhibited the mRNA and
protein expression of TRAF-6. Autophosphorylation of
IRAK promotes its dissociation from this complex,
which is followed by its polyubiquitination, and subse-
quent degradation by the 26S proteosome system
[32,12]. Our results showed that IL-1b-stimulation
caused complete degradation of IRAK compared to con-
trol, whereas pre-incubation with EGCG inhibited IRAK
degradation in OA chondrocytes. This is important
because our study identifies the EGCG mediated inhibi-
tion of IRAK degradation, a crucial event in the IL-1b-
activated signal transduction pathway, in OA chondro-
cytes may be related to its anti-inflammatory activity as
this may inhibit the signal transduction.
Studies have reported the presence of IL-1b in dis-
eased areas along with staining of TNF, IL-6 and IL-8
[33,34]. Evidence to date indicates that in addition to
IL-1, IL-6, TNF-a and IL-8 can also promote articular
cartilage extracellular matrix degradation or synergize
with other cytokines to amplify and accelerate cartilage
destruction [3-6]. Our array data showed that IL-1b-sti-
mulation of OA chondrocytes significantly induced the
mRNA as well as protein expression of IL-6, IL-8 and
TNF-a, which was significantly down-regulated by
EGCG. Using highly sensitive ELISAs, we confirmed the
array data which showed the significant dose dependent
inhibitory effect of EGCG on the IL-1b-induced produc-
tion of IL-6, IL-8 and TNF-a in OA chondrocytes. This
Figure 9 Effect of specific inhibitors of MAPKs and NF-B
pathways on the gene expression of pro-inflammatory
chemokines in IL-1b-stimulated human OA chondrocytes.
Primary chondrocytes were pretreated with specific inhibitors for 2
h and were stimulated with IL-1b for 6 h. Relative gene expression
of GRO-a (a), MCP-1 (b), MCP-2 (c), MCP-3 (d) and MIP-1b (e) was
normalized to GAPDH and compared with un-stimulated control,
were determined by quantitative RT-PCR. Concentrations of specific
inhibitors of p38 (SB202190), JNK (SP600125), ERK (PD98059) and NF-
B (MG132) used in these studies were 100 μM, 10 μM, 50 μM and
100 μM, respectively. Value represents Mean ± SD of three different
patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b
stimulated chondrocytes. GRO, growth-related oncogene; MAPKs,
mitogen activated protein kinases; MCP, monocyte chemotactic
protein; MIP, macrophage inflammatory protein; NF-B, nuclear
factor kappa-B.
Figure 10 Effect of specific inhibitors of MAPKs and NF-B
pathways on the gene expression of pro-inflammatory
cytokines and chemokines in IL-1b-stimulated human OA
chondrocytes. Primary chondrocytes were pretreated with specific
inhibitors for 2 h and were stimulated with IL-1b for 6 h. Relative
gene expression of IP-10 (a), GCP-2 (b) and NAP-2 (c) was
normalized to GAPDH and compared with un-stimulated control,
were determined by quantitative RT-PCR. Concentrations of specific
inhibitors of p38 (SB202190), JNK (SP600125), ERK (PD98059) and NF-
B (MG132) used in these studies were 100 μM, 10 μM, 50 μM and
100 μM, respectively. Value represents Mean ± SD of three different
patients. # represents P < 0.05 Vs control; * P < 0.05 Vs IL-1b
stimulated chondrocytes. GCP-2, granulocyte chemotactic protein-2;
IP-10, 10 kDa interferon gamma-induced protein; MAPKs, mitogen
activated protein kinases; NAP-2, nucleosome assembly protein-2;
NF-B, nuclear factor kappa-B.
Akhtar and Haqqi Arthritis Research & Therapy 2011, 13:R93
http://arthritis-research.com/content/13/3/R93
Page 12 of 16is supported by the previous study where EGCG was
shown to inhibit IL-6 production in RA-synovial fibro-
blasts [35]. The pro-inflammatory pathways play central
roles in the degradation of OA cartilage. IL-1b activates
multiple phosphorylation-dependent signaling pathways
including NF-B and MAPKs (that is, extracellular sig-
nal regulated kinase (ERK), c-Jun N-terminal kinase
(JNK) and p38-MAPKs), which lead to the coordinated
expression of many genes that encode cytokines, chemo-
kines, and other mediators involved in synthesis and
further amplification of the inflammatory reaction
[36,37]. We studied the involvement of NF-Ba n d
MAPKs in IL-1b mediated inflammatory response and
their regulation by EGCG. Our data showed that EGCG
inhibited the NF-B activation and JNK-activation in IL-
1b-stimulated OA chondrocytes as reported previously
[12,13]. Data obtained from NF-Bi n h i b i t o r( M G 1 3 2 )
in the presence and absence of IL-1b revealed the role
of NF-B in the regulation of IL-6, IL-8 and TNF-a in
OA chondrocytes. Recent studies have suggested that
the inhibition of NF-B activation down-regulates TNF-
a expression in AGE-BSA stimulated OA chondrocytes
[16]. In the present study, EGCG was also found to be a
potent inhibitor of the IL-1b-induced expression of IL-6
via inhibition of JNK-MAPK activation. However, modu-
latory effects of EGCG on the IL-8 and TNF-a produc-
tion appeared to be specifically via inhibition of NF-B
activation, as no role of JNK pathway was observed in
the regulation of IL-8 and TNF-a expression using a
specific inhibitor of JNK (SP600125) in IL-1b-stimulated
OA chondrocytes. Inhibition of p38-MAPK (SB202190)
was found to potently suppress the expression of IL-6,
IL-8 and TNF-a in IL-1b-stimulated OA chondrocytes
independent of NF-B inhibition. Taken together these
results suggest that activation of p38-MAPK is responsi-
ble for the optimum expression of IL-6, IL-8 and TNF-
a in IL-1b-stimulated OA chondrocytes, while JNK
appeared to be critical for the expression of IL-6 but
n o tf o rI L - 8a n dT N F - a in IL-1b-stimulated OA
chondrocytes.
LIF is a cytokine whose expression is found to be high
in OA cartilage and can be enhanced by IL-1b stimula-
tion [38,39]. Interestingly, LIF is a potent suppressor of
chondrocyte proteoglycan synthesis [40], induces col-
lagenase 3 (MMP-13) [41], IL-1 and IL-6 expression
[42] and up-regulates COX-2 and PGE2 synthesis [43].
LIF also stimulates proteoglycan resorption and its inhi-
bitors are considered to have a therapeutic potential for
the treatment of RA [44]. To our knowledge, this report
is the first demonstrating that EGCG significantly inhi-
bits LIF mRNA and protein expression in IL-1b-stimu-
lated OA chondrocytes. Thus, EGCG may be developed
as a safe and effective inhibitor of LIF in OA. Colony
stimulating factors (CSF) were among the first cytokines
found in RA synovial fluid [45], and their increased
expression was correlated with the severity of rheuma-
toid arthritis (RA) [46] and recently with OA pathogen-
esis [47]. There are numerous reports of GM-CSF
precipitating or exacerbating established inflammatory
disorders [48]. Moreover, antagonism of GM-CSF mark-
edly reduces established disease in mouse models of RA
a n dh a sac o m p a r a b l ee f f e c tt ot h a to fa n t i - T N Ft r e a t -
ment [49]. Another new gene demonstrated in this
report to be over-expressed in IL-1b-stimulated OA
chondrocytes was IL-7. Our results demonstrate for the
first time that EGCG inhibits IL-1b-induced mRNA and
protein expression of IL-7 and GMCSF in OA chondro-
cytes. IL-7 is considered as a potential contributor to
OA pathogenesis [50]. Although very little progress has
been made in developing and testing anti-IL-7 therapy
in animal models of OA, there is an increased interest
in IL-7 as a potent stimulator of matrix metalloprotei-
nase expression in OA [50,51]. In this study, we have
also investigated the role of NF-Ba n dM A P K so nt h e
EGCG mediated inhibition of LIF, GM-CSF and IL-7 in
IL-1b-stimulated chondrocytes. Our study showed that
EGCG inhibits the expression of LIF, GM-CSF and IL-7
via inhibition of NF-Bi nI L - 1 b-stimulated OA chon-
drocytes. Our results also point out that inhibition of
JNK using specific inhibitor (SP600125) in the presence
of IL-1b down-regulates LIF and IL-7 mRNA expres-
sion, suggesting the inhibition of JNK activation as an
important event in the EGCG mediated down regulation
of LIF and IL-7 expression in these cells. In this study it
was also discovered that GM-CSF expression was regu-
lated by JNK, ERK and p38-MAPKs in OA chondrocytes
in response to IL-1b. As EGCG did not inhibit ERK and
p38-MAPK activation in IL-1b-stimulated OA chondro-
cytes, EGCG mediated down-regulation of GM-CSF
expression may be mediated via NF-Bo rb yJ N K -
MAPK inhibition.
Chemokines are important regulators of chronic
inflammation, typically orchestrating leucocyte migration
and expression of chemokine receptor has been demon-
strated in chondrocytes [52] and synovial cells [53].
They have been implicated in the pathophysiology of
inflammatory diseases including OA [54,55]. Our data
demonstrated that ENA-78, GRO, GRO-a,M C P - 1a n d
3, MIP-1b,M I P - 3 a, GCP-2 and NAP-2 were expressed
and released into the medium upon stimulation with IL-
1b. Our data also showed that their induction and
expression were suppressed by EGCG in IL-1b- stimu-
lated OA chondrocytes. Secretion of IP-10 was also up-
regulated by IL-1b and inhibited by EGCG. EGCG alone
treatment was also effective in down-regulating the
basal level of expression of GRO, GRO-a,M C P - 1a n d
MIP-1b in OA chondrocytes. Consistent with the
present findings, induction of chemokines has been
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with IL-1 [56,57], but their suppression by EGCG has
not been previously described in OA chondrocytes.
However, Ahmed et al. (2006) reported similar inhibi-
tory effects of EGCG (50 μM) on RANTES, ENA-78,
GRO-a, and MCP-1 production in IL-1b-stimulated
RA-synovial fibroblasts [58]. These results indicated that
the chemokine blockade by EGCG might be a promising
novel therapeutic strategy for RA and OA. Recently,
administration of EGCG markedly diminished the sever-
ity of collagen induced arthritis, macrophage infiltration,
and the amount of CCL2-synthesizing osteoblasts [59].
Further, EGCG has been reported to decrease MCP-1
mRNA and protein expression and its receptor CCR2
expression in THP-1 cells [60]. Chemokine signaling
pathway molecules may be up-regulated in arthritis by
mechanical injury [52]. In accordance with the results of
other group, where they showed the role of NF-Bi n
EGCG mediated down regulation of chemokine produc-
tion [58], down-regulation of ENA-78, GRO, GRO-a,
MCP-1 and 3, MIP-1b,M I P - 3 a, GCP-2 and NAP-2 by
EGCG in the present study may also be mediated
through the inhibition of NF-B. Suppression of
MAPKs activation has also been linked to anti-inflam-
matory activity; we, therefore, tested whether EGCG
mediates its inhibitory effects on chemokine expression
via inhibition of MAPKs and the role of this pathway in
the regulation of these selected chemokines. In the pre-
sent study, p38-specific, JNK-specific and ERK-specific
inhibitors (SB202190, SP600125, and PD98059) reduced
the expression of ENA-78, and GRO. However, the
expression of GRO-a, IP-10 and GCP-2 was susceptible
only to inhibition of p38-MAPK activation. Expression
of MIP-1b and MCP-1 was dependent on the activation
of p38- and JNK MAPKs while expression of MCP-3
was found to be regulated by the JNK and ERK-MAPKs.
The expression level of NAP-2 was only affected by JNK
inhibition in IL-1b-stimulated OA chondrocytes.
Conclusions
In summary, our study demonstrates that EGCG exerts
differential inhibitory expression of inflammatory media-
tors in articular chondrocytes in the presence of IL-1b.
These inhibitory effects are mediated via inhibition of
MAPKs and NF-B pathways in OA chondrocytes. Our
results also demonstrate that some chemokines require
the activation of p38-MAPK for optimum expression.
The use of protein antibody array allowed the identifica-
tion of several new target proteins of EGCG in OA
chondrocytes. This provides novel insights into the anti-
inflammatory potential of EGCG on IL-1b-induced
inflammatory response. Although, EGCG did not show
direct stimulatory effect on the proteins associated with
the cartilage anabolic response, it was found to be a sur-
prisingly broad spectrum inhibitor of IL-1b-induced car-
tilage catabolic and inflammatory factors known to be
associated with the pathogenesis of arthritis. These
results support the development and use of EGCG as an
anti-inflammatory/anti-arthritic agent for prevention/
treatment of OA.
Additional material
Additional file 1: Effect of EGCG on nitrite production by human OA
chondrocytes stimulated with IL-1b. (a) Chondrocytes were pretreated
with EGCG (100 μM) for 2 h then stimulated with IL-1b (5 ng/ml) for 24
h and the culture supernatant was used for providing the cytokine
antibody array. Bar represents mean ± SD of three patients, # represents
P < 0.05 Vs control; * P < 0.05 Vs IL-1b stimulated chondrocytes. (b-e)
Represents cytokine-antibody arrays showing the effects of EGCG on the
expression pattern of cytokines produced by human OA chondrocytes
upon IL-1b-stimulation. For the array layout and identification of
cytokines please see additional file 2.
Additional file 2: Comprehensive map of cytokines antibody array.
Additional file 3: Primer sequences used to quantify gene
expression with real-time PCR.
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normal T-cell expressed and secreted; RLU: relative light units; TIMP-1: tissue
inhibitor of MMPs-1; TNF-α: tumor necrosis factor-alpha; TRAF-6: TNF
receptor-associated factor 6; VEGF: vascular endothelial growth factor.
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